Patent SG-11201901679X-A (SG)
Title: Inhibition of olig2 activity
Inventor: BEATON GRAHAM
IPC: C07D401/12
Filed: 2017-08-25
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 March 2018 (01.03.2018) W I PO I PCT omit °nolo oui No oimIE (10) International Publication Number WO 2018/039621 Al (51) International Patent Classification: C07D 401/12 (2006.01) (21) International Application Number: PCT/US2017/048716 (22) International Filing Date: 25 August 2017 (25.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/380,281 26 August 2016 (26.08.2016) US (71) Applicant: CURTANA PHARMACEUTICALS, INC. [US/US]; 1624 Headway Circle, Suite 100, Austin, Texas 78754 (US). (72) Inventors: BEATON, Graham; 18858 Bernardo Trails Drive, San Diego, California 92128 (US). MCHARDY, Stanton F.; 31 Bennitt Road, Waring, Texas 78074 (US). LOPEZ, Ambrosio, Jr.; 7803 S New Braunfels, Apt. 2208, San Antonio, Texas 78235 (US). CAMPOS, Bismarck; 7403 Tranquillo Way, San Antonio, Texas 78266 (US). WANG, Hua-Yu Leo; 5511 Pecan Springs Road, Apt. 3103, San Antonio, Texas 78249 (US). (74) Agent: MALECHA, James et al.; WILSON SONSINI GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto, California 94304 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) O (54) Title: INHIBITION OF OLIG2 ACTIVITY cc (57) : Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the ac- O tivity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma. O